(A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.
Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.
(A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.
Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.
(A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).
Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.
For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.
Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.
Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM.  Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic.  By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line.  Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. 
|体内試験||Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects.  Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors.  Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. |
Hedgehog cell assay:This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
|体外||DMF||10 mg/mL (24.29 mM) warming|
|Ethanol||2 mg/mL warmed (4.85 mM)|
10% DMSO+30% PEG 300+5% Tween 80+ddH2O
マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)
開始濃度 x 開始体積 = 最終濃度 x 最終体積
この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 輸入 輸出 )
チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2
How to reconstitute the compound for in vivo use in mice?
One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.